ATE529128T1 - Nukelinsäure kodierend für gp100 und trp2 epitope tragende immunoglobine - Google Patents

Nukelinsäure kodierend für gp100 und trp2 epitope tragende immunoglobine

Info

Publication number: ATE529128T1
Authority: AT; Austria
Prior art keywords: immunoglobins; porting; acid coding; nucleic acid; cell epitopes
Prior art date: 2007-03-28

Application number

AT10152624T

Other languages

English (en)

Inventor

Linda Gillian Durrant

Rachael Louise Metheringham

Victoria Anne Pudney

Original Assignee

Scancell Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-28

Filing date

2008-03-28

Publication date

2011-11-15

2008-03-28 Application filed by Scancell Ltd filed Critical Scancell Ltd

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE529128T1 publication Critical patent/ATE529128T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT10152624T 2007-03-28 2008-03-28 Nukelinsäure kodierend für gp100 und trp2 epitope tragende immunoglobine ATE529128T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0706070.0A GB0706070D0 (en)	2007-03-28	2007-03-28	Nucleic acids

Publications (1)

Publication Number	Publication Date
ATE529128T1 true ATE529128T1 (de)	2011-11-15

Family

ID=38050410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT10152624T ATE529128T1 (de)	2007-03-28	2008-03-28	Nukelinsäure kodierend für gp100 und trp2 epitope tragende immunoglobine

Country Status (16)

Country	Link
US (1)	US8742088B2 (de)
EP (2)	EP2134357B1 (de)
JP (1)	JP5415399B2 (de)
KR (4)	KR20100015699A (de)
CN (2)	CN103667304B (de)
AT (1)	ATE529128T1 (de)
AU (1)	AU2008231723B2 (de)
BR (1)	BRPI0808599A2 (de)
CA (1)	CA2681531C (de)
DK (2)	DK2134357T3 (de)
ES (2)	ES2638188T3 (de)
GB (1)	GB0706070D0 (de)
PL (1)	PL2134357T3 (de)
PT (2)	PT2134357T (de)
WO (1)	WO2008116937A2 (de)
ZA (1)	ZA200907242B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0706070D0 (en)	2007-03-28	2007-05-09	Scancell Ltd	Nucleic acids
GB201214007D0 (en)	2012-08-07	2012-09-19	Scancell Ltd	Anti-tumour immune responses to modified self-epitopes
AU2016215604B2 (en)	2015-02-02	2020-08-13	The University Of Birmingham	Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
WO2017210149A1 (en) *	2016-05-31	2017-12-07	Igc Bio, Inc.	Compositions and methods for generating an antibody library
US11419928B2 (en)	2017-10-25	2022-08-23	The Johns Hopkins University	Methods and compositions for treating cancer
GB201815041D0 (en)	2018-09-14	2018-10-31	Scancell Ltd	Epitopes
GB201910900D0 (en)	2019-07-31	2019-09-11	Scancell Ltd	Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
WO2021195089A1 (en)	2020-03-23	2021-09-30	Sorrento Therapeutics, Inc.	Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
CN111423504B (zh) *	2020-04-17	2021-03-26	安徽高安生物医学科技有限公司	黑色素瘤特异性抗原肽、肽复合物以及人工抗原呈递细胞
WO2022043400A1 (en)	2020-08-26	2022-03-03	Scancell Limited	Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
GB202314361D0 (en) *	2023-09-19	2023-11-01	Scancell Ltd	Vaccine compositions and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5969109A (en) *	1990-02-28	1999-10-19	Bona; Constantin	Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
CA2190101A1 (en)	1994-05-13	1995-11-23	Donald Leonard Nicholas Cardy	Improvements in or relating to peptide delivery
NZ290089A (en) *	1994-07-27	1999-05-28	Queensland Inst Med Res	Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
US5698679A (en) *	1994-09-19	1997-12-16	National Jewish Center For Immunology And Respiratory Medicine	Product and process for targeting an immune response
AUPO784197A0 (en) *	1997-07-10	1997-08-07	Csl Limited	Treatment of nasopharyngeal carcinoma
EP1030684A4 (de) *	1997-11-14	2004-09-15	Euro Celtique Sa	Modifizierte antikörper mit verstärkter fähigkeit eine anti-idiotypische antwort auszulösen
WO2000064488A2 (en) *	1999-04-27	2000-11-02	Eurogen Holding, S.A.	Somatic transgene immunization and related methods
US7067110B1 (en) *	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
GB0102145D0 (en) *	2001-01-26	2001-03-14	Scancell Ltd	Substances
GB0111628D0 (en)	2001-05-11	2001-07-04	Scancell Ltd	Binding member
WO2003018610A2 (en) *	2001-08-22	2003-03-06	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods
CA2499123A1 (en) *	2002-09-17	2004-04-15	Antigen Express, Inc.	Ii-key/antigenic epitope hybrid peptide vaccines
GB0706070D0 (en)	2007-03-28	2007-05-09	Scancell Ltd	Nucleic acids

2007
- 2007-03-28 GB GBGB0706070.0A patent/GB0706070D0/en not_active Ceased
2008
- 2008-03-28 KR KR1020097021806A patent/KR20100015699A/ko not_active Ceased
- 2008-03-28 EP EP08735583.0A patent/EP2134357B1/de active Active
- 2008-03-28 ES ES08735583.0T patent/ES2638188T3/es active Active
- 2008-03-28 KR KR1020177009184A patent/KR20170040387A/ko not_active Ceased
- 2008-03-28 EP EP10152624A patent/EP2193803B1/de active Active
- 2008-03-28 KR KR1020167020295A patent/KR101729458B1/ko active Active
- 2008-03-28 PT PT87355830T patent/PT2134357T/pt unknown
- 2008-03-28 PT PT10152624T patent/PT2193803E/pt unknown
- 2008-03-28 DK DK08735583.0T patent/DK2134357T3/en active
- 2008-03-28 BR BRPI0808599A patent/BRPI0808599A2/pt not_active Application Discontinuation
- 2008-03-28 JP JP2010500296A patent/JP5415399B2/ja active Active
- 2008-03-28 WO PCT/EP2008/053761 patent/WO2008116937A2/en not_active Ceased
- 2008-03-28 CA CA2681531A patent/CA2681531C/en active Active
- 2008-03-28 PL PL08735583T patent/PL2134357T3/pl unknown
- 2008-03-28 AU AU2008231723A patent/AU2008231723B2/en active Active
- 2008-03-28 AT AT10152624T patent/ATE529128T1/de active
- 2008-03-28 ES ES10152624T patent/ES2375463T3/es active Active
- 2008-03-28 DK DK10152624.2T patent/DK2193803T3/da active
- 2008-03-28 CN CN201310487984.6A patent/CN103667304B/zh active Active
- 2008-03-28 CN CN200880017669.4A patent/CN101678092B/zh active Active
- 2008-03-28 KR KR1020157000952A patent/KR20150013357A/ko not_active Ceased
2009
- 2009-09-24 US US12/566,465 patent/US8742088B2/en active Active
- 2009-10-16 ZA ZA2009/07242A patent/ZA200907242B/en unknown

Also Published As

Publication number	Publication date
JP2010522550A (ja)	2010-07-08
US8742088B2 (en)	2014-06-03
KR20160091458A (ko)	2016-08-02
CN101678092B (zh)	2014-04-02
KR101729458B1 (ko)	2017-04-21
DK2193803T3 (da)	2012-02-13
EP2134357B1 (de)	2017-05-31
ES2638188T3 (es)	2017-10-19
JP5415399B2 (ja)	2014-02-12
KR20170040387A (ko)	2017-04-12
DK2134357T3 (en)	2017-09-11
CN103667304A (zh)	2014-03-26
BRPI0808599A2 (pt)	2019-01-08
PT2193803E (pt)	2012-01-16
CN103667304B (zh)	2018-02-02
PT2134357T (pt)	2017-08-29
AU2008231723B2 (en)	2013-05-16
CN101678092A (zh)	2010-03-24
ZA200907242B (en)	2010-11-24
CA2681531A1 (en)	2008-10-02
US20100260806A1 (en)	2010-10-14
EP2193803B1 (de)	2011-10-19
ES2375463T3 (es)	2012-03-01
EP2193803A1 (de)	2010-06-09
GB0706070D0 (en)	2007-05-09
WO2008116937A2 (en)	2008-10-02
KR20100015699A (ko)	2010-02-12
PL2134357T3 (pl)	2018-03-30
KR20150013357A (ko)	2015-02-04
WO2008116937A3 (en)	2009-01-22
EP2134357A2 (de)	2009-12-23
CA2681531C (en)	2017-11-28
AU2008231723A1 (en)	2008-10-02

Publication	Publication Date	Title
DK2193803T3 (da)	2012-02-13	Nukleinsyrer, der koder for immunoglobiner, som bærer gp100 og TRP2-epitoper
CY1120414T1 (el)	2019-07-10	Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
AU2018256487A1 (en)	2018-11-22	Antibodies that bind to TL1A and their uses
CL2010001544A1 (es)	2012-02-03	Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
ES2430068T3 (es)	2013-11-18	Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina
CO6430469A2 (es)	2012-04-30	Anticuerpos humanizados que se unen a cd19 y sus usos
NZ623347A (en)	2014-07-25	Novel anti-dr5 antibody
ES2776179T3 (es)	2020-07-29	Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
AR105026A1 (es)	2017-08-30	ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
PE20121579A1 (es)	2012-12-13	Proteinas de enlace al antigeno il-23 humanas
CL2013003140A1 (es)	2014-05-23	Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.
PE20140133A1 (es)	2014-02-09	Nuevas proteinas de union a antigenos
NZ709390A (en)	2016-11-25	Folate receptor 1 antibodies and immunoconjugates and uses thereof
PE20141660A1 (es)	2014-11-21	PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA
RU2021103288A (ru)	2021-03-04	МОЛЕКУЛЫ СО СПЕЦИФИЧНОСТЬЮ В ОТНОШЕНИИ CD79 и CD22
PE20161439A1 (es)	2017-01-26	Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
AR070821A1 (es)	2010-05-05	Anticuerpo anti- tyrp1 (antitiroxina humana)
JP2010522550A5 (de)	2011-02-24
AR078796A1 (es)	2011-12-07	Composiciones y metodos para tratar trastornos inflamatorios
PE20161221A1 (es)	2016-11-12	Anticuerpos de il-21
CL2010000470A1 (es)	2010-09-24	Anticuerpo que se une a efrina-b2 que comprende la region variable de la cadena liviana y pesada bvr-l1, hvr-l2, hvr-h1, hvr-h2 y hvr-h3; polinucleotido que codifica dicho anticuerpo; vector y celula huesped que comprende al polinucleotido; metodo para elaborar el anticuerpo, detectar efrina-b2; y uso de dicho anticuerpo.
PH12017500699A1 (en)	2017-10-09	Antibodies that bind to ccr6 and their uses
JP2017511152A5 (de)	2018-04-19
NI201800113A (es)	2020-01-06	Anticuerpos anti-basigin humanizados y uso de los mismos.
RU2016137486A (ru)	2018-03-22	Новое антитело против pai-1 человека